China SXT Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M | $5.2M | $7.0M |
| Cost of Revenue | $889.4K | $1.4M | $1.4M | $1.5M | $1.4M | $1.9M | $2.5M | $2.4M |
| Gross Profit | $248.7K | $367.4K | $554.0K | $426.3K | $1.3M | $2.8M | $2.7M | $4.6M |
| Gross Margin | 21.9% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% |
| Operating Expenses | ||||||||
| Research & Development | — | — | $184.2K | $200.7K | $367.0K | — | — | — |
| SG&A Expense | $7.1M | $2.8M | $2.6M | $5.6M | $5.5M | $3.4M | $2.5M | $1.2M |
| Operating Income | $-7.1M | $-2.7M | $-2.5M | $-5.6M | $-5.2M | $-2.2M | $-1.3M | $1.8M |
| Operating Margin | -625.9% | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% | -26.0% | 25.2% |
| Interest Expense | — | $106.2K | $231.6K | $476.8K | $36.7K | $1.6M | $3.3M | $5.2K |
| Pretax Income | $-6.2M | $-3.3M | $-3.1M | $-5.9M | $-5.4M | $-2.9M | $-10.4M | $1.8M |
| Income Tax Expense | — | — | — | — | $328.1K | $-192.7K | $-101.7K | $252.2K |
| Net Income | $-6.2M | $-3.3M | $-3.1M | $-5.9M | $-5.7M | $-2.7M | $-10.3M | $1.5M |
| Net Margin | -545.2% | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% | -199.3% | 22.0% |
| EPS (Basic) | $-9.13 | $-348.17 | $-329.67 | $-4.56 | $-3.54 | $-0.10 | $0.43 | $0.00 |
| EPS (Diluted) | $-9.13 | $-348.17 | $-329.67 | $-4.56 | $-3.54 | $-0.10 | $0.02 | $0.00 |
| Shares Outstanding (Basic) | 679.6K | 1.4M | 1.4M | 1.3M | 1.6M | 28.1M | 24.1M | 1.60B |
| Shares Outstanding (Diluted) | 679.6K | 1.4M | 1.4M | 1.3M | 1.6M | 28.1M | 24.1M | 1.60B |
| Dividends Per Share | — | — | — | — | — | — | — | — |